osocimab subcutaneous (BAY 1213790 SC) / Bayer, Xoma - LARVOL DELTA

Pharmacokinetics and pharmacodynamics of the factor XIa-inhibiting antibody osocimab in healthy male East Asian volunteers: Results from two phase 1 studies. (PubMed, Pharmacol Res Perspect) - "The effect of osocimab on aPTT was expected per its mechanism of action. Osocimab was generally well tolerated."

Clinical • Journal • P1 data • PK/PD data • Cardiovascular

CONVERT: Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis (clinicaltrials.gov) - P2 | N=686 | Completed | Sponsor: Bayer | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Chronic Kidney Disease • Renal Disease

CONVERT: Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis (clinicaltrials.gov) - P2; N=630; Active, not recruiting; Sponsor: Bayer; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Cardiovascular • Chronic Kidney Disease • Renal Disease

CONVERT: Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis (clinicaltrials.gov) - P2; N=600; Recruiting; Sponsor: Bayer; Trial completion date: Nov 2022 ➔ Jul 2022; Trial primary completion date: Jul 2022 ➔ Feb 2022

Clinical • Trial completion date • Trial primary completion date • Cardiovascular • Chronic Kidney Disease • Renal Disease

CONVERT: Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis (clinicaltrials.gov) - P2; N=600; Recruiting; Sponsor: Bayer; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Cardiovascular • Chronic Kidney Disease • Renal Disease

CONVERT: Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis (clinicaltrials.gov) - P2; N=600; Not yet recruiting; Sponsor: Bayer

Clinical • New P2 trial • Cardiovascular • Chronic Kidney Disease • Renal Disease

Study to investigate the safety of a drug called osocimab at low and high doses in adult patients with kidney failure requiring regular hemodialysis (clinicaltrialsregister.eu) - P2; N=750; Ongoing; Sponsor: Bayer AG

Clinical • New P2 trial • Cardiovascular • Nephrology • Renal Disease